Treatment of lung cancer
AssigneeRamot at Tel-Aviv University Ltd.
InventorsYoel Kloog, Adi Zundelevich, Roni Haklai
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of treating lung cancer by administering to a human in need thereof effective amounts of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof, optionally, in combination with a chemotherapeutic agent. Chemotherapeutic agents, and combinations thereof, for use with FTS, its analogs, or its salts are also disclosed.
Claims20
A method of treating a human afflicted with lung cancer, comprising administering to the human an effective amount of FTS or an analog thereof as represented by the formula:
- wherein
- R1 represents farnesyl or geranyl-geranyl;
- R2 represents the groups COOR7, CONR7R8, wherein R7 and R8 are each independently hydrogen, alkyl or alkenyl, and COOM wherein M is a cation;
- R3, R4, R5 and R6 are each independently hydrogen, alkyl, alkenyl, alkoxy, halo, trifluoromethyl, trifluoromethoxy, or alkylmercapto;
- and
- X represents S;
- or a pharmaceutically acceptable salt thereof.
A method of treating a human afflicted with lung cancer, comprising administering to the human an effective amount of FTS or an analog thereof as represented by the formula:
- wherein
- R1 represents farnesyl or geranyl-geranyl;
- R2 represents the groups COOR7, CONR7R8, wherein R7 and R8 are each independently hydrogen, alkyl or alkenyl, and COOM wherein M is a cation;
- R3, R4, R5 and R6 are each independently hydrogen, alkyl, alkenyl, alkoxy, halo, trifluoromethyl, trifluoromethoxy, or alkylmercapto;
- and
- X represents S;
- or a pharmaceutically acceptable salt thereof,
- and
- a chemotherapeutic agent.
Dependencies are inferred from the claim text.